Most Read Articles
Rachel Soon, 07 Jun 2018

For the first time, healthcare professionals may now refer to the Malaysian Clinical Practice Guidelines on the Management of Diabetes in Pregnancy for treatment options.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Elvira Manzano, 01 Jun 2018
The use of the sodium/glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin in patients with type 2 diabetes (T2D) and moderate renal impairment provides benefits beyond glucose lowering, with no new safety signals, in the phase III DERIVE* study.
Dr Joslyn Ngu, Rachel Soon, 08 Jun 2018

In conjunction with World No-Tobacco Day 2018, MIMS speaks to Professor Dr. Mohamad Haniki Nik Mohamed about his work in expanding the MOH's integrated quit-smoking service, mQuit.

Netupitant-palonosetron combo + dexamethasone may prevent chemo-induced nausea, vomiting

Audrey Abella
02 May 2018

A single administration of the fixed-dose combination consisting of netupitant plus palonosetron (NEPA) in addition to dexamethasone may be an effective strategy for preventing chemotherapy-induced nausea and vomiting (CINV) among breast cancer patients receiving combination chemotherapy consisting of anthracycline and cyclophosphamide (AC), according to results from the GIM15-NEPA* trial presented at EBCC 2018.

A triple-drug combination consisting of an NK1RA**, a 5-HT3RA***, and dexamethasone is particularly recommended for breast cancer patients receiving AC-based chemotherapy to prevent CINV, which is likely to occur following chemotherapy due to the highly emetogenic nature of the agents used, noted the researchers.

NEPA is the first oral combination antiemetic that fulfils this requirement for the prevention of acute and delayed CINV as it consists of the highly selective NK1RA netupitant, and the 5-HT3RA palonosetron, said the researchers.

This open-label, multicentre study evaluated the efficacy of oral NEPA and dexamethasone 12 mg on 146 breast cancer patients undergoing AC-based chemotherapy. The antiemetic agents were administered on day 1 before each AC chemotherapy commenced, for a maximum of four cycles. The primary endpoint was the achievement of a complete response (CR), which pertains to the lack of emetic episode as well as the nonuse of rescue medication during the overall phase (0–120 hours) after the four cycles of chemotherapy. [EBCC-11, abstract PB-110]

The primary endpoint was achieved throughout all cycles (overall CR, 0.705, 90 percent confidence limit [CL], 0.641–0.769 for the first and second cycles; 0.724, 90 percent CL, 0.662–0.787 and 0.705, 90 percent CL, 0.642–0.770 for the third and fourth cycles, respectively).

NEPA was also well-tolerated, and most adverse events (AEs) were mild to moderate in intensity, which is consistent with the SmPC#-documented safety profile of NEPA, noted the researchers. The most common drug-related AE was fatigue (3.4 percent), followed by anaemia (2.7 percent), headache (2.1 percent), and reduction in neutrophil count (1.4 percent).

“[T]his study [demonstrated] a clinically relevant efficacy of one-day NEPA plus dexamethasone in preventing [CINV] during the entire period of … AC-based chemotherapy,” said the researchers.

These findings are consistent with evidence highlighting NEPA as a convenient, safe, and effective prophylactic antiemetic therapy for CINV, given its potential to target two antiemetic pathways with only a single dose. [Support Care Cancer 2018;26:1151-1159]

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 07 Jun 2018

For the first time, healthcare professionals may now refer to the Malaysian Clinical Practice Guidelines on the Management of Diabetes in Pregnancy for treatment options.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Elvira Manzano, 01 Jun 2018
The use of the sodium/glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin in patients with type 2 diabetes (T2D) and moderate renal impairment provides benefits beyond glucose lowering, with no new safety signals, in the phase III DERIVE* study.
Dr Joslyn Ngu, Rachel Soon, 08 Jun 2018

In conjunction with World No-Tobacco Day 2018, MIMS speaks to Professor Dr. Mohamad Haniki Nik Mohamed about his work in expanding the MOH's integrated quit-smoking service, mQuit.